TINAVI(SH:688277) Zheng Quan Zhi Xing·2025-08-27 14:02Core Points - The company announced that the second vesting period of the 2023 restricted stock incentive plan has met the vesting conditions, allowing for the vesting of 3.86466 million shares, which accounts for 0.85% of the company's total share capital [1][10][18] Group 1: Incentive Plan Overview - The total number of restricted stocks to be granted under the incentive plan is not to exceed 8.6875 million shares, with the initial grant accounting for 6.878 million shares (1.53% of total share capital) and the reserved grant accounting for 1.7195 million shares (0.38% of total share capital) [1][2] - The vesting schedule includes two periods: the first vesting period is 24 months after the initial grant, and the second vesting period is 36 months after the initial grant [2][10] Group 2: Performance Assessment Criteria - The performance assessment for the initial grant includes two conditions: a revenue growth rate of at least 90% in 2024 compared to 2022, or obtaining at least two new orthopedic surgical robots' medical device registration licenses during 2023-2024 [3][4] - For the reserved grant, the performance assessment criteria are similar but adjusted for the years 2024-2025, requiring a revenue growth rate of at least 140% in 2025 compared to 2022, or obtaining at least three new orthopedic surgical robots' medical device registration licenses during 2023-2025 [4][5] Group 3: Approval and Compliance - The incentive plan has undergone necessary approvals, including independent opinions from the board and the supervisory committee, confirming compliance with relevant regulations [6][15] - The supervisory committee verified the eligibility of 148 incentive recipients, with 95 from the initial grant and 117 from the reserved grant, confirming that the performance assessment results are compliant and truthful [18][20]